https://www.newagebd.net/article/105857/efforts-on-for-vaccine-against-covid-19
Efforts on for vaccine against COVID-19
Tapos Kanti Das | Published: 00:20, May 07,2020
Scientists across the globe are now desperately working to develop a vaccine against COVID-19 to save human lives as coronavirus infections and deaths are increasing alarmingly every day.
An Italian medical firm has claimed to have developed a vaccine that neutralises the novel coronavirus in human cells and, according to tests carried out at Rome’s infectious-disease Spallanzani Hospital, the vaccine has antibodies generated in mice that work on human cells, The Indian Express reported on Wednesday.
Tests conducted on mice by a team of scientists at Italian medical firm Takis showed they developed antibodies after a single vaccination that can block the virus from infecting human cells, the report said.
In another development, Israeli scientists at the country’s main biological research institute have made a ‘significant breakthrough’ in developing an antibody to the novel coronavirus, as the researchers wrapped up the development phase and moved to patent and mass produce the potential treatment, according to The Times of India.
So far, over 120 vaccines have been proposed across the world and World Health Organisation is tracking details on their type and progress, according to WHO website, while coronavirus continues to ravage a weary world with over 3.75 million cases and over 2,59,000 deaths as of Wednesday.
There are currently six vaccines in clinical evaluation with another about to start, and about 70 in pre-clinical evaluation, according to WHO website.
It said that the vaccines developed by CanSino Biological Inc and Beijing Institute of Biotechnology, University of Oxford, Inovio Pharmaceuticals, Beijing Institute of Biological Products and Wuhan Institute of Biological Products and Sinovac and
Moderna and NIAID are now under clinical evaluation and another developed by BioNTech/Fosun Pharma/Pfizer was approved for the evaluation.
The potential vaccine developed by Oxford University in the UK was injected to a human body on April 23 for trial and half of 1,112 healthy volunteers, aged between 18 and 55, will receive it in the first phase and the other half a control vaccine to test its safety and efficacy, according to international media.
The media reported that the scientists at the university hoped that a COVID-19 vaccine will be widely available by September.
The New York Times reported on April 22 that Germany gave the green light for human trials of potential coronavirus vaccines developed by German biotech company BioNTech, ‘which is racing teams in Germany, the US and China to develop an agent that will stop the pandemic.’
In the authorised first part of the clinical trial in Germany, 200 healthy volunteers aged between 18 and 55 years will be vaccinated, according to the Paul-Ehrlich-Institut, according to aa.com, a Turkish news portal.
In the US, the first person in clinical trials received a potential vaccine on March 16, according to drug company Moderna, reported international media and said that scientists were working on the sequence of the virus, which involves collecting samples from patients to try to develop a vaccine.
Another company, Inovio Pharmaceuticals, announced in late April that they administered its vaccine to 40 healthy volunteers.
In China, Xinhua News Agency reported in mid-April, the country approved human testing of two vaccines developed by the Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Company Ltd, a company based in Beijing.
In Turkey, thirty-two scientists are working to create an antigen designed to induce an immune response to the virus. The research is conducted jointly by the Drug Development and Pharmacokinetic Research Application Center at Izmir’s Ege University and the Scientific and Technological Research Council of Turkey, Turkish newspaper Daily Sabah reported in mid-April.
The newspaper quoted a scientist as saying that they would apply them to an animal model within four months and hoped to begin human clinical trials as soon as possible.
Efforts on for vaccine against COVID-19
Tapos Kanti Das | Published: 00:20, May 07,2020
Scientists across the globe are now desperately working to develop a vaccine against COVID-19 to save human lives as coronavirus infections and deaths are increasing alarmingly every day.
An Italian medical firm has claimed to have developed a vaccine that neutralises the novel coronavirus in human cells and, according to tests carried out at Rome’s infectious-disease Spallanzani Hospital, the vaccine has antibodies generated in mice that work on human cells, The Indian Express reported on Wednesday.
Tests conducted on mice by a team of scientists at Italian medical firm Takis showed they developed antibodies after a single vaccination that can block the virus from infecting human cells, the report said.
In another development, Israeli scientists at the country’s main biological research institute have made a ‘significant breakthrough’ in developing an antibody to the novel coronavirus, as the researchers wrapped up the development phase and moved to patent and mass produce the potential treatment, according to The Times of India.
So far, over 120 vaccines have been proposed across the world and World Health Organisation is tracking details on their type and progress, according to WHO website, while coronavirus continues to ravage a weary world with over 3.75 million cases and over 2,59,000 deaths as of Wednesday.
There are currently six vaccines in clinical evaluation with another about to start, and about 70 in pre-clinical evaluation, according to WHO website.
It said that the vaccines developed by CanSino Biological Inc and Beijing Institute of Biotechnology, University of Oxford, Inovio Pharmaceuticals, Beijing Institute of Biological Products and Wuhan Institute of Biological Products and Sinovac and
Moderna and NIAID are now under clinical evaluation and another developed by BioNTech/Fosun Pharma/Pfizer was approved for the evaluation.
The potential vaccine developed by Oxford University in the UK was injected to a human body on April 23 for trial and half of 1,112 healthy volunteers, aged between 18 and 55, will receive it in the first phase and the other half a control vaccine to test its safety and efficacy, according to international media.
The media reported that the scientists at the university hoped that a COVID-19 vaccine will be widely available by September.
The New York Times reported on April 22 that Germany gave the green light for human trials of potential coronavirus vaccines developed by German biotech company BioNTech, ‘which is racing teams in Germany, the US and China to develop an agent that will stop the pandemic.’
In the authorised first part of the clinical trial in Germany, 200 healthy volunteers aged between 18 and 55 years will be vaccinated, according to the Paul-Ehrlich-Institut, according to aa.com, a Turkish news portal.
In the US, the first person in clinical trials received a potential vaccine on March 16, according to drug company Moderna, reported international media and said that scientists were working on the sequence of the virus, which involves collecting samples from patients to try to develop a vaccine.
Another company, Inovio Pharmaceuticals, announced in late April that they administered its vaccine to 40 healthy volunteers.
In China, Xinhua News Agency reported in mid-April, the country approved human testing of two vaccines developed by the Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Company Ltd, a company based in Beijing.
In Turkey, thirty-two scientists are working to create an antigen designed to induce an immune response to the virus. The research is conducted jointly by the Drug Development and Pharmacokinetic Research Application Center at Izmir’s Ege University and the Scientific and Technological Research Council of Turkey, Turkish newspaper Daily Sabah reported in mid-April.
The newspaper quoted a scientist as saying that they would apply them to an animal model within four months and hoped to begin human clinical trials as soon as possible.
